ABIVAX Société Anonyme (AAVXF)
USD 11.05
(0.0%)
USD 11.05
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -196.47 Million EUR | -1127.5% |
| 2022 | 19.12 Million EUR | 364.01% |
| 2021 | -7.24 Million EUR | -254.17% |
| 2020 | 4.69 Million EUR | -57.21% |
| 2019 | 10.97 Million EUR | 278.03% |
| 2018 | 2.9 Million EUR | 279.37% |
| 2017 | -1.61 Million EUR | 78.76% |
| 2016 | -7.62 Million EUR | 69.17% |
| 2015 | -24.72 Million EUR | -2944.89% |
| 2014 | 868.96 Thousand EUR | 247.85% |
| 2013 | -587.71 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -111.17 Million EUR | 2.0% |
| 2024 Q1 | -111.17 Million EUR | 43.42% |
| 2023 FY | -196.47 Million EUR | -1127.5% |
| 2023 Q3 | -177.85 Million EUR | -123.17% |
| 2023 Q1 | -73.46 Million EUR | -484.16% |
| 2023 Q4 | -196.47 Million EUR | -10.47% |
| 2023 Q2 | -79.69 Million EUR | -8.49% |
| 2022 Q1 | 22.27 Million EUR | 407.59% |
| 2022 Q4 | 19.12 Million EUR | -12.03% |
| 2022 Q3 | 21.73 Million EUR | -41.72% |
| 2022 Q2 | 37.29 Million EUR | 67.39% |
| 2022 FY | 19.12 Million EUR | 364.01% |
| 2021 Q2 | 27.47 Million EUR | 0.07% |
| 2021 Q3 | -9.21 Million EUR | -133.55% |
| 2021 Q4 | -7.24 Million EUR | 21.43% |
| 2021 FY | -7.24 Million EUR | -254.17% |
| 2021 Q1 | 27.46 Million EUR | 484.5% |
| 2020 Q1 | 12.43 Million EUR | 13.23% |
| 2020 Q2 | 12.43 Million EUR | 0.01% |
| 2020 Q3 | 4.68 Million EUR | -62.3% |
| 2020 Q4 | 4.69 Million EUR | 0.26% |
| 2020 FY | 4.69 Million EUR | -57.21% |
| 2019 Q4 | 10.97 Million EUR | 0.0% |
| 2019 Q1 | 10.25 Million EUR | 252.96% |
| 2019 Q3 | 10.97 Million EUR | 7.1% |
| 2019 FY | 10.97 Million EUR | 278.03% |
| 2019 Q2 | 10.25 Million EUR | 0.0% |
| 2018 Q3 | 2.9 Million EUR | 212.86% |
| 2018 FY | 2.9 Million EUR | 279.37% |
| 2018 Q2 | -2.57 Million EUR | 0.0% |
| 2018 Q1 | -2.57 Million EUR | -58.93% |
| 2018 Q4 | 2.9 Million EUR | 0.0% |
| 2017 Q4 | -1.61 Million EUR | 13.93% |
| 2017 Q3 | -1.88 Million EUR | -99.05% |
| 2017 Q2 | -945 Thousand EUR | 0.0% |
| 2017 Q1 | -945 Thousand EUR | 87.6% |
| 2017 FY | -1.61 Million EUR | 78.76% |
| 2016 Q2 | -715 Thousand EUR | 0.0% |
| 2016 Q4 | -7.62 Million EUR | 0.0% |
| 2016 Q3 | -7.62 Million EUR | -965.87% |
| 2016 Q1 | -715 Thousand EUR | 97.11% |
| 2016 FY | -7.62 Million EUR | 69.17% |
| 2015 FY | -24.72 Million EUR | -2944.89% |
| 2015 Q3 | 316 Thousand EUR | 100.6% |
| 2015 Q4 | -24.72 Million EUR | -7923.1% |
| 2015 Q1 | -51.55 Million EUR | -6032.72% |
| 2015 Q2 | -53.1 Million EUR | -3.0% |
| 2014 Q4 | 868.96 Thousand EUR | -0.0% |
| 2014 Q3 | 869 Thousand EUR | 0.0% |
| 2014 Q1 | 40 Thousand EUR | 0.0% |
| 2014 FY | 868.96 Thousand EUR | 247.85% |
| 2013 FY | -587.71 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 1346.451% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 4871.172% |
| SQZ Biotechnologies Company | -36.23 Million USD | -442.188% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 559.136% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -3016.46% |
| Mesoblast Limited | 55.85 Million USD | 451.744% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 21290.786% |
| Genus plc | 190.6 Million USD | 203.084% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 8887.691% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 16285.843% |
| Marizyme, Inc. | 18.56 Million USD | 1158.095% |
| ContraFect Corporation | -6.02 Million USD | -3160.504% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 28993.824% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 146029.486% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 17104.766% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 8862.604% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 3671.096% |
| MultiCell Technologies, Inc. | 90.04 USD | 218212005.82% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -26668.922% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 1617.673% |
| EV Biologics, Inc. | 1.36 Million USD | 14462.731% |
| Q BioMed Inc. | 4.06 Million USD | 4939.35% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 743.052% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 31669.628% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 19597.358% |
| Biomind Labs Inc. | 711.4 Thousand USD | 27718.421% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 278.935% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 1634.195% |
| Skye Bioscience, Inc. | -5.72 Million USD | -3334.096% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 22939.879% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 140638.182% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 3578.49% |
| IMV Inc. | 7.67 Million USD | 2661.469% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 989066.628% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 9022.784% |
| GB Sciences, Inc. | 1.74 Million USD | 11344.56% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -106804.695% |
| HST Global, Inc. | 96.79 Thousand USD | 203087.819% |
| CSL Limited | 10.52 Billion USD | 101.867% |
| Halberd Corporation | 144.72 Thousand USD | 135863.296% |
| Enzolytics Inc. | 981.65 Thousand USD | 20114.954% |
| Resverlogix Corp. | 6.45 Million USD | 3145.698% |
| Affymax, Inc. | -5.59 Million USD | -3410.416% |
| SYBLEU INC | 473.71 Thousand USD | 41576.081% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -29090.493% |
| argenx SE | -2.02 Billion USD | 90.316% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 552.36% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -317.932% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 7353.818% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -2122.624% |
| AVAX Technologies, Inc. | -5.9 Million USD | -3228.326% |
| Zenith Capital Corp. | 10.06 Thousand USD | 1952385.374% |
| Genscript Biotech Corporation | -1.06 Billion USD | 81.488% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 98127.261% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 8334.501% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 119532.979% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 424.512% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 9926.887% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -7544.963% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 54721.223% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 1069.018% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -1072495.261% |
| BioStem Technologies, Inc. | 4.47 Million USD | 4493.504% |
| ONE Bio Corp. | 9.04 Million USD | 2273.421% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 97726.879% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -14998220.611% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 95377.305% |
| Agentix Corp. | 37.63 Thousand USD | 522217.403% |
| LadRx Corporation | -2.03 Million USD | -9547.974% |
| Cell Source, Inc. | 9.23 Million USD | 2228.235% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -962649.902% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 31033.282% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 31033.282% |
| NovAccess Global Inc. | 2.17 Million USD | 9119.103% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 2878.656% |
| Itoco Inc. | 228.3 Thousand USD | 86159.438% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 144580.804% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 4063.647% |
| Kadimastem Ltd | -253.1 Thousand USD | -77527.992% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 48993.49% |
| CytoDyn Inc. | 20.26 Million USD | 1069.687% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -30367442.504% |
| Mobile Lads Corp. | 484.23 Thousand USD | 40675.179% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -2119783.388% |
| Qrons Inc. | 351.42 Thousand USD | 56008.624% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 2649.675% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -78610.84% |
| Rebus Holdings, Inc. | 305 Thousand USD | 64519.016% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 4508.28% |
| International Stem Cell Corporation | 2.59 Million USD | 7686.023% |
| Bioxytran, Inc. | 1.89 Million USD | 10446.861% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 314903.006% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 9109.033% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 5821.549% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 2397.182% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 25530.523% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -15618.24% |
| Neutra Corp. | 52.18 Thousand USD | 376588.397% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -7793.853% |
| PureTech Health plc | -167.19 Million USD | -17.513% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -80125.227% |
| IXICO plc | -4.44 Million USD | -4320.613% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 1586.33% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 458.203% |
| CSL Limited | 10.52 Billion USD | 101.867% |
| Cellectis S.A. | -43.81 Million USD | -348.387% |